{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:32:27Z","timestamp":1781019147597,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773203"],"award-info":[{"award-number":["81773203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670177"],"award-info":[{"award-number":["81670177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970182"],"award-info":[{"award-number":["81970182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060041"],"award-info":[{"award-number":["82060041"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institutional Review Board of the Fudan University Shanghai Cancer Center, Shanghai, China","award":["050432-4-1212B"],"award-info":[{"award-number":["050432-4-1212B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12185-024-03877-y","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T14:03:19Z","timestamp":1733407399000},"page":"194-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-\u03baB"],"prefix":"10.1007","volume":"121","author":[{"given":"Feng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuguang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jennifer","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"issue":"7","key":"3877_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"issue":"12","key":"3877_CR2","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496\u2013504. https:\/\/doi.org\/10.1182\/blood-2008-01-134270.","journal-title":"Blood"},{"issue":"2","key":"3877_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.seminhematol.2021.02.006","volume":"58","author":"I Nizamuddin","year":"2021","unstructured":"Nizamuddin I, Galvez C, Pro B. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin. Semin Hematol. 2021;58(2):85\u201394. https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.006.","journal-title":"Semin Hematol"},{"issue":"3","key":"3877_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Trumper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288\u201398. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002.","journal-title":"Ann Oncol"},{"issue":"3","key":"3877_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2022;40(3):242\u201351. https:\/\/doi.org\/10.1200\/JCO.21.01815.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3877_CR6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.218305","volume":"104","author":"M Bellei","year":"2019","unstructured":"Bellei M, Federico M. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective international T-cell project. Haematologica. 2019;104(4): e178. https:\/\/doi.org\/10.3324\/haematol.2019.218305.","journal-title":"Haematologica"},{"issue":"25","key":"3877_CR7","doi-asserted-by":"publisher","first-page":"23180","DOI":"10.1074\/jbc.M301863200","volume":"278","author":"PC Evans","year":"2003","unstructured":"Evans PC, Smith TS, Lai MJ, Williams MG, Burke DF, Heyninck K, et al. A novel type of deubiquitinating enzyme. J Biol Chem. 2003;278(25):23180\u20136. https:\/\/doi.org\/10.1074\/jbc.M301863200.","journal-title":"J Biol Chem"},{"issue":"11","key":"3877_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41419-022-05379-3","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S, Cai K, Zheng D, Liu Y, Li L, He Z, et al. RHBDL2 promotes the proliferation, migration, and invasion of pancreatic cancer by stabilizing the N1ICD via the OTUD7B and activating the Notch signaling pathway. Cell Death Dis. 2022;13(11):945. https:\/\/doi.org\/10.1038\/s41419-022-05379-3.","journal-title":"Cell Death Dis"},{"issue":"6","key":"3877_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41419-021-03785-7","volume":"12","author":"J Tang","year":"2021","unstructured":"Tang J, Wu Z, Tian Z, Chen W, Wu G. OTUD7B stabilizes estrogen receptor alpha and promotes breast cancer cell proliferation. Cell Death Dis. 2021;12(6):534. https:\/\/doi.org\/10.1038\/s41419-021-03785-7.","journal-title":"Cell Death Dis"},{"issue":"7654","key":"3877_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nature22344","volume":"545","author":"B Wang","year":"2017","unstructured":"Wang B, Jie Z, Joo D, Ordureau A, Liu P, Gan W, et al. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling. Nature. 2017;545(7654):365\u20139. https:\/\/doi.org\/10.1038\/nature22344.","journal-title":"Nature"},{"issue":"9","key":"3877_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.428","volume":"8","author":"JH Wang","year":"2017","unstructured":"Wang JH, Zhong XP, Zhang YF, Wu XL, Li SH, Jian PE, et al. Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell Death Dis. 2017;8(9): e3043. https:\/\/doi.org\/10.1038\/cddis.2017.428.","journal-title":"Cell Death Dis"},{"issue":"7437","key":"3877_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature11831","volume":"494","author":"H Hu","year":"2013","unstructured":"Hu H, Brittain GC, Chang JH, Puebla-Osorio N, Jin J, Zal A, et al. OTUD7B controls non-canonical NF-kappaB activation through deubiquitination of TRAF3. Nature. 2013;494(7437):371\u20134. https:\/\/doi.org\/10.1038\/nature11831.","journal-title":"Nature"},{"issue":"3","key":"3877_CR13","doi-asserted-by":"publisher","first-page":"998","DOI":"10.7150\/jca.65835","volume":"13","author":"S Qiu","year":"2022","unstructured":"Qiu S, Liu Y, Gui A, Xia Z, Liu W, Gu JJ, et al. Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma. J Cancer. 2022;13(3):998\u20131004. https:\/\/doi.org\/10.7150\/jca.65835.","journal-title":"J Cancer"},{"issue":"20","key":"3877_CR14","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"issue":"43","key":"3877_CR15","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1038\/onc.2011.587","volume":"31","author":"F Pareja","year":"2012","unstructured":"Pareja F, Ferraro DA, Rubin C, Cohen-Dvashi H, Zhang F, Aulmann S, et al. Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. Oncogene. 2012;31(43):4599\u2013608. https:\/\/doi.org\/10.1038\/onc.2011.587.","journal-title":"Oncogene"},{"key":"3877_CR16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3389\/fonc.2019.00862","volume":"9","author":"DD Lin","year":"2019","unstructured":"Lin DD, Shen Y, Qiao S, Liu WW, Zheng L, Wang YN, et al. Upregulation of OTUD7B (Cezanne) promotes tumor progression via AKT\/VEGF pathway in lung squamous carcinoma and adenocarcinoma. Front Oncol. 2019;9:862. https:\/\/doi.org\/10.3389\/fonc.2019.00862.","journal-title":"Front Oncol"},{"issue":"1","key":"3877_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13046-020-01751-3","volume":"39","author":"B Zhang","year":"2020","unstructured":"Zhang B, Yang C, Wang R, Wu J, Zhang Y, Liu D, et al. OTUD7B suppresses Smac mimetic-induced lung cancer cell invasion and migration via deubiquitinating TRAF3. J Exp Clin Cancer Res. 2020;39(1):244. https:\/\/doi.org\/10.1186\/s13046-020-01751-3.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"3877_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.prp.2016.07.011","volume":"212","author":"B Zhang","year":"2016","unstructured":"Zhang B, Wang H, Yang L, Zhang Y, Wang P, Huang G, et al. OTUD7B and NIK expression in non-small cell lung cancer: association with clinicopathological features and prognostic implications. Pathol Res Pract. 2016;212(10):893\u20138. https:\/\/doi.org\/10.1016\/j.prp.2016.07.011.","journal-title":"Pathol Res Pract"},{"key":"3877_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12967-015-0396-1","volume":"13","author":"JH Wang","year":"2015","unstructured":"Wang JH, Wei W, Guo ZX, Shi M, Guo RP. Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. J Transl Med. 2015;13:41. https:\/\/doi.org\/10.1186\/s12967-015-0396-1.","journal-title":"J Transl Med"},{"issue":"3","key":"3877_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1084\/jem.20151426","volume":"213","author":"H Hu","year":"2016","unstructured":"Hu H, Wang H, Xiao Y, Jin J, Chang JH, Zou Q, et al. Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination. J Exp Med. 2016;213(3):399\u2013414. https:\/\/doi.org\/10.1084\/jem.20151426.","journal-title":"J Exp Med"},{"issue":"1","key":"3877_CR21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s43018-020-00161-w","volume":"2","author":"CS Moon","year":"2021","unstructured":"Moon CS, Reglero C, Cortes JR, Quinn SA, Alvarez S, Zhao J, et al. FYN-TRAF3IP2 induces NF-kappaB signaling-driven peripheral T cell lymphoma. Nat Cancer. 2021;2(1):98\u2013113. https:\/\/doi.org\/10.1038\/s43018-020-00161-w.","journal-title":"Nat Cancer"},{"issue":"1","key":"3877_CR22","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1038\/s41467-021-24037-4","volume":"12","author":"K Debackere","year":"2021","unstructured":"Debackere K, Marcelis L, Demeyer S, Vanden Bempt M, Mentens N, Gielen O, et al. Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified. Nat Commun. 2021;12(1):3705. https:\/\/doi.org\/10.1038\/s41467-021-24037-4.","journal-title":"Nat Commun"},{"issue":"9","key":"3877_CR23","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1158\/1078-0432.CCR-12-3151","volume":"19","author":"L Odqvist","year":"2013","unstructured":"Odqvist L, Sanchez-Beato M, Montes-Moreno S, Martin-Sanchez E, Pajares R, Sanchez-Verde L, et al. NIK controls classical and alternative NF-kappaB activation and is necessary for the survival of human T-cell lymphoma cells. Clin Cancer Res. 2013;19(9):2319\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3151.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"3877_CR24","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132(21):2305\u20139. https:\/\/doi.org\/10.1182\/blood-2018-04-840538.","journal-title":"Blood"},{"issue":"11","key":"3877_CR25","doi-asserted-by":"publisher","first-page":"e972","DOI":"10.1016\/j.clml.2022.07.009","volume":"22","author":"SE Yoon","year":"2022","unstructured":"Yoon SE, Cho J, Kim YJ, Kim SJ, Kim WS. Real-world efficacy of 5-azacytidine as salvage chemotherapy for angioimmunoblastic T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2022;22(11):e972\u201380. https:\/\/doi.org\/10.1016\/j.clml.2022.07.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"3877_CR26","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1182\/blood.2022018254","volume":"141","author":"J Ruan","year":"2023","unstructured":"Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023;141(18):2194\u2013205. https:\/\/doi.org\/10.1182\/blood.2022018254.","journal-title":"Blood"},{"issue":"10044","key":"3877_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(16)00739-X.","journal-title":"Lancet"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03877-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03877-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03877-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T16:35:21Z","timestamp":1738254921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03877-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3877"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03877-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Fudan University Shanghai Cancer Center (No. 050432\u20134-1212B).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}